Cinacalcet (Sensipar) for secondary hyperparathyroidism in chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1465
- Available Online
- View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinac…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Cinacalcet
- Renal Insufficiency, Chronic - drug therapy
- Hyperparathyroidism, Secondary - drug therapy
- Subjects (LCSH)
- Chronic renal failure
- Hyperparathyroidism
- Kidneys--Diseases--Treatment
- Abstract
- Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinacalcet, possible side effects, and how to store this medication.
- Notes
- Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
- Previous title: Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1465
Dialysis patients : being prepared for an emergency
https://libcat.nshealth.ca/en/permalink/chpams35535
Nova Scotia Health Authority. Community Dialysis.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1564
- Available Online
- View Pamphlet
This pamphlet provides instructions on what dialysis patients should do if an emergency prevents them from starting or finishing their dialysis treatment at home or attending an appointment for dialysis. It explains what precautions to take, who to contact in an emergency, and what medications to take, and provides answers to common questions. The French version of this pamphlet 1901, "Patients recevant de la dialyse : se préparer en cas d’urgence", is also available.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Community Dialysis
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (6 p.) : digital, PDF file
- Subjects (MeSH)
- Kidney Diseases - therapy
- Dialysis
- Subjects (LCSH)
- Kidneys--Diseases--Treatment
- Dialysis
- Abstract
- This pamphlet provides instructions on what dialysis patients should do if an emergency prevents them from starting or finishing their dialysis treatment at home or attending an appointment for dialysis. It explains what precautions to take, who to contact in an emergency, and what medications to take, and provides answers to common questions. The French version of this pamphlet 1901, "Patients recevant de la dialyse : se préparer en cas d’urgence", is also available.
- Responsibility
- Prepared by: Community Dialysis
- Pamphlet Number
- 1564
Kidney Health Clinic : Yarmouth kidney care services
https://libcat.nshealth.ca/en/permalink/chpams36563
Nova Scotia Health Authority. Yarmouth Regional Hospital, Kidney Health Clinic.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1991
- Available Online
- View Pamphlet
The Kidney Health Clinic is for patients diagnosed with Chronic Kidney Disease (CKD). CKD means having kidney damage or a lower level of kidney function for 3 months or more. The goal of the Kidney Clinic is to stop or slow down the progression of kidney disease. This pamphlet lists the team members you will meet at the clinic and what to expect when you come to the clinic. Contact information is also provided.
- Available Online
- View Pamphlet
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([6] p.) : digital, PDF file
- Subjects (MeSH)
- Kidney Diseases - therapy
- Subjects (LCSH)
- Kidneys--Diseases--Treatment
- Abstract
- The Kidney Health Clinic is for patients diagnosed with Chronic Kidney Disease (CKD). CKD means having kidney damage or a lower level of kidney function for 3 months or more. The goal of the Kidney Clinic is to stop or slow down the progression of kidney disease. This pamphlet lists the team members you will meet at the clinic and what to expect when you come to the clinic. Contact information is also provided.
- Responsibility
- Prepared by: Kidney Health Clinic, Yarmouth Regional Hospital
- Pamphlet Number
- 1991
Kidney transplantation : practical guide to management
https://libcat.nshealth.ca/en/permalink/provcat33425
Matthew R. Weir, Edgar V. Lerma, editors.
--New York:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
With the increased prevalence of kidney transplantation, transplant recipients are being treated in a variety of clinical settings - often beyond the transplant center. There is a greater need for clinicians and allied healthcare professionals to have appropriate guidance on managing these patients. Kidney Transplantation offers the latest evidence-based information on the full range of dilemmas in the medical management of kidney transplant recipients before, during and after transplantation. …
- Available Online
- View e-Book
- Other Authors
- Weir, Matthew R
- Lerma, Edgar V
- Responsibility
- Matthew R. Weir, Edgar V. Lerma, editors
- Place of Publication
- New York
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xvi, 438 pages)
- ISBN
- 9781493903429 (electronic bk.)
- 9781493903412
- Subjects (MeSH)
- Kidney Transplantation
- Transplantation Immunology
- Abstract
- With the increased prevalence of kidney transplantation, transplant recipients are being treated in a variety of clinical settings - often beyond the transplant center. There is a greater need for clinicians and allied healthcare professionals to have appropriate guidance on managing these patients. Kidney Transplantation offers the latest evidence-based information on the full range of dilemmas in the medical management of kidney transplant recipients before, during and after transplantation. Beginning with the selection of patients who are candidates for transplantation, this authoritative guide covers the care of the patient on the waiting list and evaluation of donors, preoperative care, induction and immunosuppression maintenance. This wealth of new information and guidelines will serve as an important resource for the best possible care for transplant patients.
- Contents
- 1. Graft and Patient Survival -- 2. Immunological Assessment of the Transplant Patient -- 3. Recipient Evaluation -- 4. Wait List Management -- 5. Approach to the Highly Sensitized Patient -- 6. Simultaneous Paired Kidney Exchange -- 7. Ethical Issues and Transplant Tourism -- 8. Live Donor Transplantation -- 9. Extended Criteria Donors in Renal Transplantation -- 10. Preoperative Cardiovascular Evaluation and Management -- 11. Surgical Issues in the Transplant Recipient -- 12. Mechanisms of Immunosuppressive Drugs -- 13. Delayed Graft Function and Kidney Transplantation -- 14. Evaluation and Initial Management of Graft Dysfunction -- 15. Recurrent and De Novo Diseases After Renal Transplantation -- 16. Psychosocial Issues in Renal Transplantation -- 17. Risks of Pregnancy in Renal Transplant Recipients -- 18. The Prevention and Treatment of Coronary Artery Disease in Kidney Transplant Recipients -- 19. Dyslipidemia After Kidney Transplantation -- 20. Hypertension in the Kidney Transplant Recipient -- 21. Evaluation and Management of Transplant-Associated Hyperglycemia -- 22. Hematologic Complications of Transplantation -- 23. Liver Disease in Renal Transplant Recipients -- 24. Management of Transplantation Renal Bone Disease: Interplay of Bone Mineral Density and Decisions Regarding Bisphosphonate Use -- 25. Malignancies After Transplantation and Posttransplant Lymphoproliferative Disorder -- 26. Antibody-Mediated Rejection in Kidney Transplantation -- 27. Prevention and Management of Infectious Complications in Kidney Transplant Recipients -- 28. Human Polyomavirus (HPyV) and Organ Transplantation -- 29. Post-transplant Proteinuria: Differential Diagnosis and Management -- 30. Urologic Issues in the Renal Transplant Patient -- 31. Practical Renal Allograft Pathology -- 32. Imaging of the Renal Transplant Recipient -- 33. Kidney and Pancreas Transplantation -- 34. Drug Interactions in Solid Organ Transplant Recipients.
- Format
- e-Book
- Location
- Online
Lanthanum (Fosrenol) and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1466
- Available Online
- View Pamphlet
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Lanthanum
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like lanthanam to remove more. Fosrenol® is the brand name for lanthanum. This pamphlet explains how to take lanthanum, possible side effects, and how to store this medication.
- Notes
- Previous title: Fosrenol (Lanthanum) and hemodialysis
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1466
One-Alpha® (alfacalcidol) and hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1470
- Available Online
- View Pamphlet
One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Pharmacy Services
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. One-Alpha® is a brand name for alfacalcidol.
- Responsibility
- Prepared by: Renal Pharmacy Team, NSHA Renal Program
- Pamphlet Number
- 1470
Patients recevant de la dialyse : se préparer en cas d’urgence
https://libcat.nshealth.ca/en/permalink/chpams36461
Nova Scotia Health Authority. Community Dialysis.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1901
- Available Online
- View Pamphlet
La présente brochure fournit des instructions sur ce que devraient faire les personnes dialysées si une urgence les empêche de commencer ou de terminer leur traitement de dialyse à la maison ou de se rendre à un rendez-vous de dialyse. Elle explique les précautions à prendre, indique avec qui communiquer en cas d’urgence et précise les médicaments à prendre. Elle répond aussi à des questions fréquemment posées. ; This pamphlet is a French translation of "Dialysis Patients: Being Prepared for an…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Community Dialysis
- Alternate Title
- Dialysis patients : being prepared for an emergency
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- French
- Physical Description
- 1 electronic document (6 p.) : digital, PDF file
- Subjects (MeSH)
- Kidney Diseases - therapy
- Dialysis
- Subjects (LCSH)
- Kidneys--Diseases--Treatment
- Dialysis
- Abstract
- La présente brochure fournit des instructions sur ce que devraient faire les personnes dialysées si une urgence les empêche de commencer ou de terminer leur traitement de dialyse à la maison ou de se rendre à un rendez-vous de dialyse. Elle explique les précautions à prendre, indique avec qui communiquer en cas d’urgence et précise les médicaments à prendre. Elle répond aussi à des questions fréquemment posées.
- This pamphlet is a French translation of "Dialysis Patients: Being Prepared for an Emergency" pamphlet 1564. This pamphlet provides instructions on what dialysis patients should do if an emergency prevents them from starting or finishing their dialysis treatment at home or attending an appointment for dialysis. It explains what precautions to take, who to contact in an emergency, and what medications to take, and provides answers to common questions.
- Responsibility
- Prepared by: Community Dialysis
- Pamphlet Number
- 1901
Practical nephrology
https://libcat.nshealth.ca/en/permalink/provcat33452
Mark Harber, editor.
--London:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
This book will provide readers with a practice-based approach to all aspects of clinical nephrology. Written by experts in the field, Practical Nephrology offers invaluable practical advice on how to manage specific illnesses and, uniquely, the importance of establishing systems and processes to improve patient safety, enhance the patient pathway and guidance on how to systematically improve clinical governance. A unique aspect of this book are the tips and tricks and, suggestions for avoiding …
- Available Online
- View e-Book
- Other Authors
- Harber, Mark
- Responsibility
- Mark Harber, editor
- Place of Publication
- London
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xix, 901 pages)
- ISBN
- 9781447155478 (electronic bk.)
- 9781447155461
- Subjects (MeSH)
- Kidney Diseases
- Nephrology - methods
- Abstract
- This book will provide readers with a practice-based approach to all aspects of clinical nephrology. Written by experts in the field, Practical Nephrology offers invaluable practical advice on how to manage specific illnesses and, uniquely, the importance of establishing systems and processes to improve patient safety, enhance the patient pathway and guidance on how to systematically improve clinical governance. A unique aspect of this book are the tips and tricks and, suggestions for avoiding common errors based on the vast experience of the authors. In addition, the Editor has collated a list of links to international registries and guidelines as well as selected disease specific organisations, providing both clinicians and patients with access to helpful and recommended resources. Designed and written in a user-friendly fashion, Practical Nephrology will be the definitive reference for practising nephrologists, trainees and non-nephrologist who encounter renal patients in their daily practice.
- Contents
- Assessment of the Renal Patient -- Urine Analysis -- Imaging in Nephrology -- Kidney Biopsy -- Acute Kidney Injury: Epidemiology and Assessment -- Acute Kidney Injury: Management and Prevention -- Acute Renal Replacement Therapy -- Hepatorenal Syndrome -- Common Electrolyte Disorders -- Acid-Base Disorders -- Diagnosis and Investigation of the Hypertensive Patient -- Management of High Blood Pressure -- Podocytopathies -- Management of the Nephrotic Patient: The Overall Approach to the Patient with Nephrotic Syndrome (NS) -- Management of the Nephrotic Patient: Treatment of ECF Volume Expansion Due to Nephrotic Syndrome in Adults -- Minimal Change Disease and Focal Segmental Glomerulosclerosis -- Membranous Nephropathy -- Membranoproliferative Glomerulonephritis and C3 Glomerulopathy -- IgA Nephropathy and Henoch-Schonlein Purpura -- Systemic Small Vessel Vasculitis -- Goodpasture's or Anti-glomerular Basement Membrane (GBM) Disease -- Systemic Lupus Erythematosus, Antiphospholipid Syndrome and the Kidney -- Practical Immunosuppression Guidelines for Patients with Glomerulonephritis -- Infectious Diseases and the Kidney -- Blood-Borne Viruses and the Kidney -- Tubulointerstitial Nephritis -- Rheumatological Conditions and the Kidney -- Multiple Myeloma and the Kidney -- Amyloidosis -- Thrombotic Microangiopathies -- Sickle Cell Disease and Other Haematological Disorders Involving the Kidney -- Diabetes and the Kidney -- Pregnancy and the Kidney -- Disease of the Renal Vessels -- Urinary Tract Infection -- Renal Stone Disease -- Congenital Anomalies of the Kidneys and Urinary Tract -- Acquired Urinary Tract Obstruction -- Kidney Cancer -- Inherited Renal Tumour Syndromes -- Polycystic Kidney Disease -- Other Cystic Kidney Diseases -- Genetic Disorders of the Glomerular Basement Membrane -- Anderson-Fabry Disease and Other Inherited Lipid Disorders of the Kidney -- Inherited Metabolic Disease -- Dermatology in Kidney Disease -- Chronic Kidney Disease: Epidemiology and Causes -- Chronic Kidney Disease: Management -- Transition -- Anaemia Management in Chronic Kidney Disease -- Chronic Kidney Disease: Mineral and Bone Disorder (CKD-MBD) -- Chronic Kidney Disease: Cardiovascular Complications -- Coagulation in Kidney Disease -- Symptom Control and Palliative Care in Advanced CKD -- Nutrition and Kidney Disease -- Pharmacology and the Kidney -- Prevention of Infection in Kidney Patients -- Setting Up and Running a Haemodialysis Service -- Vascular Access: Improving Outcomes for Haemodialysis Patients -- Vascular Access: Fistulae and Grafts -- Complications of Maintenance Haemodialysis and How to Avoid Them -- Providing a Peritoneal Dialysis Service -- Peritoneal Dialysis Prescription -- Complications of Peritoneal Dialysis and How to Avoid Them -- Assessment of the Potential Transplant Donor -- Assessment of the Potential Transplant Recipient -- Tissue Typing, Crossmatch and Antibody Incompatibility in Kidney Transplantation -- Surgical Aspects of Kidney and Pancreas Transplantation -- Management of the Acute Transplant -- Immunosuppression for Kidney Transplantation -- Infectious Complications of Transplantation -- Long-Term Management of Kidney Transplant Recipients (KTRs) -- International Health Partnerships.
- Format
- e-Book
- Location
- Online
Rocaltrol® (calcitriol) and hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1468
- Available Online
- View Pamphlet
Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Pharmacy Services
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Calcitriol
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. Rocaltrol® is a brand name for calcitriol.
- Responsibility
- Prepared by: Renal Pharmacy Team, NSHA Renal Program
- Pamphlet Number
- 1468
Sevelamer (Renagel) and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35372
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1464
- Available Online
- View Pamphlet
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra ph…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Sevelamer
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Subjects (LCSH)
- Hemodialysis
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Abstract
- Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like sevelamer to remove more. Renagel® is one brand name for sevelamer. This pamphlet explains how to take sevelamer, possible side effects, and how to store this medication.
- Notes
- Previous title: Renagel (Sevelamer) and Hemodialysis
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1464
Velphoro® (sucroferric oxyhydroxide) and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams37620
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 2307
- Available Online
- View Pamphlet
Velphoro® is a medication used to treat high levels of phosphorous in the blood. Phosphorous is a mineral that builds strong bones and teeth. Velphoro® binds (attaches) to phosphorous from the foods you eat and stops your body from taking it in. This pamphlet explains why someone with with chronic kidney disease (CKD) needs to take this medication, how to take and store it, and possible side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([2] p.) : digital, PDF file
- Subjects (MeSH)
- Kidney Diseases - drug therapy
- Subjects (LCSH)
- Kidneys--Diseases--Treatment
- Specialty
- Nephrology
- Medications
- Abstract
- Velphoro® is a medication used to treat high levels of phosphorous in the blood. Phosphorous is a mineral that builds strong bones and teeth. Velphoro® binds (attaches) to phosphorous from the foods you eat and stops your body from taking it in. This pamphlet explains why someone with with chronic kidney disease (CKD) needs to take this medication, how to take and store it, and possible side effects.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 2307
